These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 21459260)
1. Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Katz PM; Mendelsohn AA; Goodman SG; Langer A; Teoh H; Leiter LA Can J Cardiol; 2011; 27(2):138-45. PubMed ID: 21459260 [TBL] [Abstract][Full Text] [Related]
2. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA; Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714 [TBL] [Abstract][Full Text] [Related]
3. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
4. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E; J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Jones PH; Goldberg AC; Knapp HR; Kelly MT; Setze CM; Stolzenbach JC; Sleep DJ Am Heart J; 2010 Oct; 160(4):759-66. PubMed ID: 20934572 [TBL] [Abstract][Full Text] [Related]
6. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Gotto AM; Farmer JA Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799 [TBL] [Abstract][Full Text] [Related]
7. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [TBL] [Abstract][Full Text] [Related]
9. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Yan AT; Yan RT; Tan M; Hackam DG; Leblanc KL; Kertland H; Tsang JL; Jaffer S; Kates ML; Leiter LA; Fitchett DH; Langer A; Goodman SG; Am J Med; 2006 Aug; 119(8):676-83. PubMed ID: 16887414 [TBL] [Abstract][Full Text] [Related]
10. Colesevelam hydrochloride in the management of dyslipidemia. Armani A; Toth PP Expert Rev Cardiovasc Ther; 2006 May; 4(3):283-91. PubMed ID: 16716090 [TBL] [Abstract][Full Text] [Related]
11. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. Gupta M; Szmitko PE; Tsigoulis M; Braga MF; Kajil M; Herjikaka S; Quan A; Teoh H; Verma S J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518 [TBL] [Abstract][Full Text] [Related]
12. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Sorensen SV; Frick KD; Wade A; Simko R; Burge R Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159 [TBL] [Abstract][Full Text] [Related]
13. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Daskalopoulou SS; Mikhailidis DP Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035 [TBL] [Abstract][Full Text] [Related]
14. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Ahmed MH; Khalil AA Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168 [TBL] [Abstract][Full Text] [Related]
15. Clinical use of ezetimibe. Cheng AY; Leiter LA Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Petrella RJ; Merikle E; Jones J Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298 [TBL] [Abstract][Full Text] [Related]
18. Achieving vascular risk factor targets: a survey of a London general practice. Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M Angiology; 2008; 59(1):36-46. PubMed ID: 18319220 [TBL] [Abstract][Full Text] [Related]
19. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction. Ballantyne CM Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009 [TBL] [Abstract][Full Text] [Related]
20. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. Sampalis JS; Bissonnette S; Habib R; Boukas S; Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]